Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback